EUVIMEDEUVIMED entdecken
Fallbericht

Epstein Barr virus‐directed T‐cell therapy for refractory EBV‐PTLD in a toddler post Orthotopic heart transplantation

Emily Work, Dipankar Gupta iD, William B Slayton, John Rees, John-Anthony Coppola, Robert Seifert iD, Mark S Bleiweis, Jeffrey P Jacobs, Giles Peek iD, Joseph Philip, Alan Brock, Jose Hernandez Rivera und 2 weitere

Pediatric Transplantation · 2024

DOI: 10.1111/petr.14707 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Pediatric Transplantation, 2024. Verfasst von Emily Work und 13 weiteren Autor:innen. Beteiligte Einrichtung: University of Florida, Gainesville, Florida, USA. Hauptthemen laut MEDLINE: Epstein-Barr Virus Infections, Heart Transplantation, Lymphoproliferative Disorders, Hematopoietic Stem Cell Transplantation. Die Arbeit nennt 9 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epstein–Barr Virus (EBV) is a ubiquitous herpes type virus that is associated with post‐transplant lymphoproliferative disorder (PTLD). Usual management includes reduction or cessation of immunosuppression and in some cases chemotherapy including rituximab. However, limited therapies are available if PTLD is refractory to rituximab. Several clinical trials have investigated the use of EBV‐directed T cells in rituximab‐refractory patients; however, data regarding response is scarce and inconclusive. Herein, we describe a patient with EBV‐PTLD refractory to rituximab after orthotopic heart transplantation (OHT) requiring EBV‐directed T‐cell therapy. This article aims to highlight the unique and aggressive clinical presentation and progression of PTLD with utilization of EBV‐directed T‐cell therapy for management and associated pitfalls.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epstein-Barr Virus InfectionsHeart TransplantationLymphoproliferative DisordersHematopoietic Stem Cell TransplantationHumansChild, PreschoolHerpesvirus 4, HumanRituximabCell- and Tissue-Based Therapy

Stichwörter der Autor:innen

Epstein-Barr virusPTLDcardiac transplantationrejectionrituximab

Substanzen

Rituximab

Autor:innen und Institutionen

  • University of Florida, Gainesville, Florida, USA.
  • Congenital Heart Center, University of Florida, Gainesville, Florida, USA.
  • Division of Hematology and Oncology, University of Florida, Gainesville, Florida, USA.
  • Department of Radiology, University of Florida, Gainesville, Florida, USA.
  • Department of Pathology, University of Florida, Gainesville, Florida, USA.

ORCID-Profile: Dipankar Gupta, Robert Seifert, Giles Peek, Sukumar Suguna Narasimhulu

Zitieren

APA

Work, E., Gupta, D., Slayton, W. B., Rees, J., Coppola, J. A., Seifert, R., Bleiweis, M. S., Jacobs, J. P., Peek, G., Philip, J., Brock, A., Rivera, J. H., Sullivan, K., & Narasimhulu, S. S. (2024). Epstein Barr virus‐directed T‐cell therapy for refractory EBV‐PTLD in a toddler post Orthotopic heart transplantation. Pediatric Transplantation. https://doi.org/10.1111/petr.14707

Vancouver

Work E, Gupta D, Slayton WB, Rees J, Coppola JA, Seifert R, et al. Epstein Barr virus‐directed T‐cell therapy for refractory EBV‐PTLD in a toddler post Orthotopic heart transplantation. Pediatric Transplantation. 2024. doi:10.1111/petr.14707

BibTeX
@article{Work2024,
  author = {Work, Emily and Gupta, Dipankar and Slayton, William B and Rees, John and Coppola, John-Anthony and Seifert, Robert and Bleiweis, Mark S and Jacobs, Jeffrey P and Peek, Giles and Philip, Joseph and Brock, Alan and Rivera, Jose Hernandez and Sullivan, Kevin and Narasimhulu, Sukumar Suguna},
  title = {Epstein Barr virus‐directed T‐cell therapy for refractory EBV‐PTLD in a toddler post Orthotopic heart transplantation},
  journal = {Pediatric Transplantation},
  year = {2024},
  doi = {10.1111/petr.14707}
}
Kostenlos starten →